During the last decade, chimeric antigen receptor (CAR)-T-cell therapies targeting CD19 and B cell maturation antigen (BCMA) have revolutionized the management of multiple advanced hematologic malignancies. This evidence concerns the gene TNFRSF17 and hematologic disorder.